11/19
07:00 am
scyx
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
Low
Report
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
11/17
10:15 am
scyx
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
Low
Report
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
11/12
01:30 pm
scyx
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:15 am
scyx
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
SCYNEXIS (NASDAQ:SCYX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/5
04:20 pm
scyx
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/28
08:43 am
scyx
SCYNEXIS (NASDAQ:SCYX) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
Medium
Report
SCYNEXIS (NASDAQ:SCYX) had its price target lowered by analysts at Guggenheim from $4.00 to $3.00. They now have a "buy" rating on the stock.
10/25
01:31 am
scyx
Low
Report
10/15
08:00 am
scyx
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
Low
Report
SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
9/30
08:00 am
scyx
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
High
Report
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
9/10
01:40 pm
scyx
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer's Disease Program [Yahoo! Finance]
Low
Report
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer's Disease Program [Yahoo! Finance]